Publications by authors named "M Voskoboynik"
Article Synopsis
- Lutetium-177 [Lu]Lu-PSMA-617 is being studied for its effectiveness in improving survival and quality of life for patients with metastatic castration-resistant prostate cancer, but its benefits for hormone-sensitive prostate cancer are still unclear.
- The UpFrontPSMA trial involved patients with high-volume metastatic hormone-sensitive prostate cancer, who were randomly assigned to receive either [Lu]Lu-PSMA-617 followed by docetaxel or docetaxel alone as standard care.
- The primary goal of the trial was to determine if patients treated with [Lu]Lu-PSMA-617 could achieve undetectable levels of prostate-specific antigen (PSA) after 48 weeks.
This first-in-human study evaluated safety and efficacy of CD40 agonist MEDI5083 with durvalumab in patients with advanced solid tumors. Patients received MEDI5083 (3-7.5 mg subcutaneously every 2 weeks × 4 doses) and durvalumab (1500 mg every 4 weeks) either sequentially (N = 29) or concurrently (N = 9).
View Article and Find Full Text PDFArticle Synopsis
- - Davoceticept (ALPN-202) is an experimental treatment designed to enhance immune response by targeting PD-L1 and CTLA-4, and its effectiveness was assessed in two studies: NEON-1 (monotherapy) and NEON-2 (in combination with pembrolizumab) on patients with advanced solid tumors.
- - In NEON-1, 58 participants received varying doses of davoceticept, and in NEON-2, 29 patients received davoceticept alongside pembrolizumab, with safety and efficacy monitored through adverse events and tumor response.
- - Results indicated that 67% of participants in NEON-1 and 62% in NEON-
Purpose: SHR-A1811 is an antibody-drug conjugate composed of an anti-human epidermal growth factor receptor 2 (HER2) antibody trastuzumab, a cleavable linker, and a topoisomerase I inhibitor payload. We assessed the safety, tolerability, antitumor activity, and pharmacokinetics of SHR-A1811 in heavily pretreated HER2-expressing or mutated advanced solid tumors.
Methods: This global, multi-center, first-in-human, phase I trial was conducted at 33 centers.
Background: Enzalutamide and lutetium-177 [Lu]Lu-prostate-specific membrane antigen (PSMA)-617 both improve overall survival in patients with metastatic castration-resistant prostate cancer. Androgen and PSMA receptors have a close intracellular relationship, with data suggesting complementary benefit if targeted concurrently. In this study, we assessed the activity and safety of enzalutamide plus adaptive-dosed [Lu]Lu-PSMA-617 versus enzalutamide alone as first-line treatment for metastatic castration-resistant prostate cancer.
View Article and Find Full Text PDF